vs

Side-by-side financial comparison of UNIVERSAL CORP (UVV) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

DENTSPLY SIRONA Inc. is the larger business by last-quarter revenue ($961.0M vs $853.2M, roughly 1.1× UNIVERSAL CORP). UNIVERSAL CORP runs the higher net margin — 3.9% vs -15.2%, a 19.1% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs -8.1%). UNIVERSAL CORP produced more free cash flow last quarter ($95.1M vs $60.0M). Over the past eight quarters, UNIVERSAL CORP's revenue compounded faster (6.2% CAGR vs 0.4%).

Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

UVV vs XRAY — Head-to-Head

Bigger by revenue
XRAY
XRAY
1.1× larger
XRAY
$961.0M
$853.2M
UVV
Growing faster (revenue YoY)
XRAY
XRAY
+14.3% gap
XRAY
6.2%
-8.1%
UVV
Higher net margin
UVV
UVV
19.1% more per $
UVV
3.9%
-15.2%
XRAY
More free cash flow
UVV
UVV
$35.1M more FCF
UVV
$95.1M
$60.0M
XRAY
Faster 2-yr revenue CAGR
UVV
UVV
Annualised
UVV
6.2%
0.4%
XRAY

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
UVV
UVV
XRAY
XRAY
Revenue
$853.2M
$961.0M
Net Profit
$33.2M
$-146.0M
Gross Margin
17.8%
46.1%
Operating Margin
9.6%
-14.5%
Net Margin
3.9%
-15.2%
Revenue YoY
-8.1%
6.2%
Net Profit YoY
-44.2%
66.0%
EPS (diluted)
$1.32
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
UVV
UVV
XRAY
XRAY
Q4 25
$853.2M
$961.0M
Q3 25
$749.4M
$904.0M
Q2 25
$592.6M
$936.0M
Q1 25
$690.2M
$879.0M
Q4 24
$928.0M
$905.0M
Q3 24
$708.4M
$951.0M
Q2 24
$596.4M
$984.0M
Q1 24
$756.3M
$953.0M
Net Profit
UVV
UVV
XRAY
XRAY
Q4 25
$33.2M
$-146.0M
Q3 25
$34.2M
$-427.0M
Q2 25
$8.5M
$-45.0M
Q1 25
$9.3M
$20.0M
Q4 24
$59.6M
$-430.0M
Q3 24
$25.9M
$-494.0M
Q2 24
$130.0K
$-4.0M
Q1 24
$40.3M
$18.0M
Gross Margin
UVV
UVV
XRAY
XRAY
Q4 25
17.8%
46.1%
Q3 25
18.0%
48.8%
Q2 25
19.1%
52.4%
Q1 25
15.1%
53.0%
Q4 24
19.9%
49.3%
Q3 24
19.9%
52.1%
Q2 24
16.0%
51.9%
Q1 24
18.0%
53.1%
Operating Margin
UVV
UVV
XRAY
XRAY
Q4 25
9.6%
-14.5%
Q3 25
9.0%
-24.1%
Q2 25
5.7%
-13.7%
Q1 25
6.2%
7.2%
Q4 24
11.2%
-56.2%
Q3 24
9.7%
-48.6%
Q2 24
2.9%
5.1%
Q1 24
9.0%
4.4%
Net Margin
UVV
UVV
XRAY
XRAY
Q4 25
3.9%
-15.2%
Q3 25
4.6%
-47.2%
Q2 25
1.4%
-4.8%
Q1 25
1.4%
2.3%
Q4 24
6.4%
-47.5%
Q3 24
3.7%
-51.9%
Q2 24
0.0%
-0.4%
Q1 24
5.3%
1.9%
EPS (diluted)
UVV
UVV
XRAY
XRAY
Q4 25
$1.32
$-0.74
Q3 25
$1.36
$-2.14
Q2 25
$0.34
$-0.22
Q1 25
$0.37
$0.10
Q4 24
$2.37
$-2.09
Q3 24
$1.03
$-2.46
Q2 24
$0.01
$-0.02
Q1 24
$1.62
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
UVV
UVV
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$85.2M
$326.0M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$1.5B
$1.3B
Total Assets
$3.0B
$5.4B
Debt / EquityLower = less leverage
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
UVV
UVV
XRAY
XRAY
Q4 25
$85.2M
$326.0M
Q3 25
$88.7M
$363.0M
Q2 25
$178.4M
$359.0M
Q1 25
$260.1M
$398.0M
Q4 24
$215.1M
$272.0M
Q3 24
$80.1M
$296.0M
Q2 24
$101.7M
$279.0M
Q1 24
$55.6M
$291.0M
Total Debt
UVV
UVV
XRAY
XRAY
Q4 25
$2.3B
Q3 25
Q2 25
Q1 25
Q4 24
$1.7B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
UVV
UVV
XRAY
XRAY
Q4 25
$1.5B
$1.3B
Q3 25
$1.5B
$1.5B
Q2 25
$1.5B
$2.0B
Q1 25
$1.5B
$2.0B
Q4 24
$1.5B
$1.9B
Q3 24
$1.4B
$2.5B
Q2 24
$1.4B
$3.1B
Q1 24
$1.4B
$3.3B
Total Assets
UVV
UVV
XRAY
XRAY
Q4 25
$3.0B
$5.4B
Q3 25
$3.1B
$5.7B
Q2 25
$3.2B
$6.1B
Q1 25
$3.0B
$6.0B
Q4 24
$3.0B
$5.8B
Q3 24
$3.0B
$6.6B
Q2 24
$3.0B
$6.9B
Q1 24
$2.9B
$7.1B
Debt / Equity
UVV
UVV
XRAY
XRAY
Q4 25
1.70×
Q3 25
Q2 25
Q1 25
Q4 24
0.90×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
UVV
UVV
XRAY
XRAY
Operating Cash FlowLast quarter
$114.3M
$101.0M
Free Cash FlowOCF − Capex
$95.1M
$60.0M
FCF MarginFCF / Revenue
11.1%
6.2%
Capex IntensityCapex / Revenue
2.3%
4.3%
Cash ConversionOCF / Net Profit
3.44×
TTM Free Cash FlowTrailing 4 quarters
$52.7M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
UVV
UVV
XRAY
XRAY
Q4 25
$114.3M
$101.0M
Q3 25
$32.7M
$79.0M
Q2 25
$-205.1M
$48.0M
Q1 25
$158.7M
$7.0M
Q4 24
$215.6M
$87.0M
Q3 24
$15.0M
$141.0M
Q2 24
$-62.4M
$208.0M
Q1 24
$-27.9M
$25.0M
Free Cash Flow
UVV
UVV
XRAY
XRAY
Q4 25
$95.1M
$60.0M
Q3 25
$23.7M
$40.0M
Q2 25
$-217.2M
$16.0M
Q1 25
$151.0M
$-12.0M
Q4 24
$199.6M
$36.0M
Q3 24
$-1.0M
$98.0M
Q2 24
$-85.2M
$156.0M
Q1 24
$-46.2M
$-9.0M
FCF Margin
UVV
UVV
XRAY
XRAY
Q4 25
11.1%
6.2%
Q3 25
3.2%
4.4%
Q2 25
-36.6%
1.7%
Q1 25
21.9%
-1.4%
Q4 24
21.5%
4.0%
Q3 24
-0.1%
10.3%
Q2 24
-14.3%
15.9%
Q1 24
-6.1%
-0.9%
Capex Intensity
UVV
UVV
XRAY
XRAY
Q4 25
2.3%
4.3%
Q3 25
1.2%
4.3%
Q2 25
2.0%
3.4%
Q1 25
1.1%
2.2%
Q4 24
1.7%
5.6%
Q3 24
2.3%
4.5%
Q2 24
3.8%
5.3%
Q1 24
2.4%
3.6%
Cash Conversion
UVV
UVV
XRAY
XRAY
Q4 25
3.44×
Q3 25
0.96×
Q2 25
-24.14×
Q1 25
17.00×
0.35×
Q4 24
3.62×
Q3 24
0.58×
Q2 24
-480.34×
Q1 24
-0.69×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

UVV
UVV

Tobacco Operations$779.9M91%
Service Other$36.7M4%
Other$17.8M2%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons